{"entity":{"id":"2007","kind":"year","name":"2007 in oncology","aka":["2007"],"tldr":"Everything OnCo dates to 2007: 129 entries, 37 papers listed on people's pages, 26 landmarks, 25 papers and 18 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"129 dated entries in OnCo fall in 2007: 37 papers listed on people's pages, 26 landmarks, 25 papers, 18 approvals, 6 companies founded, 6 journals founded, 5 trials reported, 4 technologies, 1 law or regulation and 1 regulatory event.\n\nOf those, 1 to the day and 128 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2006","2008"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2007,"events":[{"group":"approval","date":"2007","precision":"year","title":"5-Aminolevulinic acid (oral, for glioma surgery) approved in EU","note":"Visualisation of malignant tissue during surgery for WHO grade III-IV glioma","from":"aminolevulinic-acid-gleolan","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Dexrazoxane approved in US","note":"Anthracycline extravasation (Totect)","from":"dexrazoxane","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Epoetin alfa approved in EU","note":"First epoetin alfa biosimilars (Binocrit, Abseamed, Epoetin alfa Hexal) including chemotherapy-induced anaemia","from":"epoetin-alfa","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Erlotinib approved in EU","note":"Metastatic pancreatic cancer with gemcitabine (Tarceva product information: factors associated with prolonged survival should be taken into account when prescribing; 100 mg daily)...","from":"erlotinib","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"HPV bivalent vaccine (types 16 and 18) approved in EU","note":"Prevention of premalignant cervical lesions and cervical cancer caused by HPV 16 and 18 from age 9 (Cervarix); anal lesions added later","from":"hpv-bivalent-vaccine","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Ixabepilone approved in US","note":"Metastatic or locally advanced breast cancer after anthracycline and taxane (with capecitabine) or after anthracycline, taxane and capecitabine (monotherapy)","from":"ixabepilone","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Lapatinib approved in US","note":"HER2+ advanced breast cancer with capecitabine after trastuzumab","from":"lapatinib","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"MammaPrint (70-gene signature) approved in US","note":"FDA 510(k) clearance for recurrence risk in early breast cancer","from":"mammaprint","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Nelarabine approved in EU","note":"T-ALL and T-LBL after at least two regimens (Atriance)","from":"nelarabine","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Nilotinib approved in EU","note":"Ph+ CML","from":"nilotinib","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Nilotinib approved in US","note":"Ph+ CML, chronic or accelerated phase, resistant/intolerant to imatinib","from":"nilotinib","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Panitumumab approved in EU","note":"Metastatic colorectal cancer; RAS wild-type from 2013. Vectibix marketing authorisation issued 3 December 2007.","from":"panitumumab","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Raloxifene approved in US","note":"Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk","from":"raloxifene","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Sorafenib approved in US","note":"Unresectable HCC","from":"sorafenib","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Temsirolimus approved in EU","note":"Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009","from":"temsirolimus","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Temsirolimus approved in US","note":"Advanced renal cell carcinoma","from":"temsirolimus","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Topotecan approved in US","note":"Relapsed SCLC (oral)","from":"topotecan","refs":[]},{"group":"approval","date":"2007","precision":"year","title":"Trabectedin approved in EU","note":"Advanced soft-tissue sarcoma after anthracycline/ifosfamide","from":"trabectedin","refs":[]},{"group":"company","date":"2007","precision":"year","title":"Acacia Pharma founded","note":"Cambridge","from":"acacia-pharma","refs":[]},{"group":"company","date":"2007","precision":"year","title":"BioAtla founded","note":"San Diego, California","from":"bioatla","refs":[]},{"group":"company","date":"2007","precision":"year","title":"Chinese Thoracic Oncology Group founded","note":"Guangzhou","from":"ctong","refs":[]},{"group":"company","date":"2007","precision":"year","title":"P-Cure founded","note":"Jerusalem","from":"p-cure","refs":[]},{"group":"company","date":"2007","precision":"year","title":"Stella Pharma founded","note":"Osaka","from":"stella-pharma","refs":[]},{"group":"company","date":"2007","precision":"year","title":"Third Rock Ventures founded","note":"Boston, MA","from":"third-rock-ventures","refs":[]},{"group":"history","date":"2007","precision":"year","title":"'Triple-negative' enters clinical vocabulary","note":"Triple-negative breast cancer (TNBC). Defined by absence of ER, PR, HER2; recognised as the subtype with the fewest treatment options, which set the research agenda that followed.","from":"tnbc","refs":[]},{"group":"history","date":"2007","precision":"year","title":"Adjuvant mitotane associated with longer recurrence-free survival (Terzolo, NEJM)","note":"Adrenocortical carcinoma","from":"adrenocortical","refs":["mitotane"]},{"group":"history","date":"2007","precision":"year","title":"Cladribine reported as active in advanced mastocytosis","note":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","from":"advanced-systemic-mastocytosis","refs":["cladribine"]},{"group":"history","date":"2007","precision":"year","title":"CONKO-001: adjuvant gemcitabine after resection lengthens disease-free survival","note":"Resectable pancreatic ductal adenocarcinoma","from":"resectable-pdac","refs":["gemcitabine"]},{"group":"history","date":"2007","precision":"year","title":"CONKO-001: adjuvant gemcitabine doubles disease-free survival","note":"Pancreatic ductal adenocarcinoma. 368 patients; 13.4 versus 6.9 months.","from":"pancreatic","refs":["paper-conko-001-adjuvant-gemcitabine-observation-jama-2007","conko-001"]},{"group":"history","date":"2007","precision":"year","title":"EML4-ALK fusion discovered","note":"Non-small-cell lung cancer. Soda et al.; crizotinib approved 2011.","from":"nsclc","refs":["alk"]},{"group":"history","date":"2007","precision":"year","title":"EML4-ALK fusion discovered in lung cancer (Soda and Mano, Japan)","note":"ALK-positive non-small-cell lung cancer","from":"alk-positive-nsclc","refs":["alk","gene-fusion"]},{"group":"history","date":"2007","precision":"year","title":"EML4-ALK: the second driver","note":"Lung cancer (all types). A small inversion on chromosome 2p, found in 5 of 75 tumours, transformed fibroblasts.","from":"lung-cancer","refs":["paper-soda-eml4-alk-fusion-nature-2007","paper-kwak-crizotinib-alk-nsclc-nejm-2010"]},{"group":"history","date":"2007","precision":"year","title":"Fallopian tube fimbria identified as the origin of serous cancer","note":"High-grade serous ovarian cancer","from":"high-grade-serous-ovarian-cancer","refs":[]},{"group":"history","date":"2007","precision":"year","title":"Fallopian tube identified as origin of high-grade serous cancer","note":"Ovarian cancer. Serous tubal intraepithelial carcinoma described in BRCA carriers' prophylactic specimens; leads to salpingectomy-based prevention.","from":"ovarian","refs":["hgsoc","risk-reducing-salpingectomy"]},{"group":"history","date":"2007","precision":"year","title":"GOG-0161: ifosfamide-paclitaxel improves survival over ifosfamide alone","note":"Uterine carcinosarcoma","from":"uterine-carcinosarcoma","refs":["ifosfamide","paclitaxel"]},{"group":"history","date":"2007","precision":"year","title":"Interfant-99 reports four-year event-free survival of 47 percent","note":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","from":"all-infant","refs":[]},{"group":"history","date":"2007","precision":"year","title":"Lapatinib: first HER2 pill","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["lapatinib"]},{"group":"history","date":"2007","precision":"year","title":"Mayo series: about 10 percent a year progress in the first five years","note":"Smouldering multiple myeloma","from":"smouldering-myeloma","refs":["smoldering-myeloma"]},{"group":"history","date":"2007","precision":"year","title":"QUASAR measures the stage II benefit","note":"Colorectal cancer. 3,239 patients, 91 percent node-negative: relative risk of death 0.82, an absolute survival gain of about 3.6 percent.","from":"colorectal","refs":["paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007"]},{"group":"history","date":"2007","precision":"year","title":"Residual cancer burden score; the relapse curve that peaks at three years","note":"Triple-negative breast cancer (TNBC). Symmans graded residual disease after neoadjuvant chemotherapy; Dent's Toronto cohort showed distant relapse hazard ratio 2.6 peaking at three...","from":"tnbc","refs":["paper-symmans-j-clin-oncol","paper-dent-tnbc-clinical-features-recurrence-ccr-2007","rcb"]},{"group":"history","date":"2007","precision":"year","title":"Residual disease found in 46 percent of re-resections for incidental cancer","note":"Gallbladder cancer. Pawlik and colleagues, six centres, 115 patients: the observational basis for re-resecting T1b or deeper tumours.","from":"gallbladder","refs":["paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007","radical-cholecystectomy"]},{"group":"history","date":"2007","precision":"year","title":"Resistance without touching the target","note":"Non-small-cell lung cancer. MET amplification restores the growth signal through ERBB3 in 4 of 18 lung cancers resistant to an EGFR inhibitor, defining bypass resistance as a categ...","from":"nsclc","refs":["paper-engelman-met-amplification-gefitinib-resistance-science-2007","met"]},{"group":"history","date":"2007","precision":"year","title":"Retrospective Italian-German study associates adjuvant mitotane with longer recurrence-free survival","note":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","from":"localised-adrenocortical-carcinoma","refs":["mitotane"]},{"group":"history","date":"2007","precision":"year","title":"ROS1 fusions identified in lung cancer","note":"ROS1-positive non-small-cell lung cancer","from":"ros1-positive-nsclc","refs":["ros1","gene-fusion"]},{"group":"history","date":"2007","precision":"year","title":"SHARP: sorafenib, the first systemic therapy","note":"Hepatocellular carcinoma","from":"hcc","refs":["sharp","sorafenib"]},{"group":"history","date":"2007","precision":"year","title":"Slotman: prophylactic cranial irradiation improves survival in extensive stage when brain imaging is not routine","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["slotman-pci-es-sclc","prophylactic-cranial-irradiation"]},{"group":"history","date":"2007","precision":"year","title":"Sorafenib: first systemic therapy","note":"Hepatocellular carcinoma","from":"hcc","refs":[]},{"group":"history","date":"2007","precision":"year","title":"Trabectedin approved in Europe for soft-tissue sarcoma","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["trabectedin"]},{"group":"history","date":"2007","precision":"year","title":"Trabectedin approved in Europe for soft-tissue sarcoma","note":"Leiomyosarcoma","from":"leiomyosarcoma","refs":["trabectedin"]},{"group":"history","date":"2007","precision":"year","title":"Triple-negative defined as a clinical entity","note":"Early triple-negative breast cancer","from":"tnbc-early","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"Cell Stem Cell founded","note":"Cell Press (Elsevier)","from":"cell-stem-cell","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"Head and neck pathology founded","note":"Springer","from":"head-and-neck-pathology","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"Journal of cancer survivorship founded","note":"Springer Nature","from":"journal-of-cancer-survivorship","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"Journal of gastrointestinal cancer founded","note":"Springer Nature","from":"journal-of-gastrointestinal-cancer","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"Molecular oncology founded","note":"Wiley on behalf of FEBS","from":"molecular-oncology","refs":[]},{"group":"journal","date":"2007","precision":"year","title":"The Gulf journal of oncology founded","note":"Gulf Federation for Cancer Control","from":"gulf-journal-of-oncology","refs":[]},{"group":"law","date":"2007","precision":"year","title":"Abigail Alliance v. von Eschenbach (2007)","note":"United States, court ruling.","from":"abigail-alliance","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients","note":"Montgomery GH, Bovbjerg DH, Schnur JB, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-montgomery-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","note":"Quasar Collaborative Group, Gray R, Barnwell J, et al. The Lancet.","from":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","note":"Oettle H, Post S, Neuhaus P, et al. JAMA.","from":"paper-conko-001-adjuvant-gemcitabine-observation-jama-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","note":"Hillmen P, Skotnicki AB, Robak T, et al. Journal of Clinical Oncology.","from":"paper-hillmen-j-clin-oncol","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Aneuploidy acts both oncogenically and as a tumor suppressor","note":"Weaver BA, Silk AD, Montagna C, et al. Cancer Cell.","from":"paper-weaver-cancer-cell","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","note":"Xing M. Endocrine reviews.","from":"paper-braf-thyroid-endocr-rev-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-neg...","note":"Bauer KR, Brown M, Cress RD, et al. Cancer.","from":"paper-bauer-triple-negative-california-registry-cancer-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","note":"Sankaranarayanan R, Esmy PO, Rajkumar R, et al. The Lancet.","from":"paper-sankaranarayanan-lancet","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer","note":"Oba K, Teramukai S, Kobayashi M, et al. Cancer immunology, immunotherapy.","from":"paper-oba-cancer-immunol-immunother","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","note":"Dewey A, Baughan C, Dean T, et al. The Cochrane database of systematic reviews.","from":"paper-dewey-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","note":"Soda M, Choi YL, Enomoto M, et al. Nature.","from":"paper-soda-eml4-alk-fusion-nature-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection","note":"Pawlik TM, Gleisner AL, Vigano L, et al. Journal of Gastrointestinal Surgery.","from":"paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and...","note":"Pierce JP, Natarajan L, Caan BJ, et al. JAMA.","from":"paper-whel-jama-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","note":"Pieters R, Schrappe M, De Lorenzo P, et al. The Lancet.","from":"paper-interfant-99-lancet-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Jemal 2007: Cancer statistics, 2007","note":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. CA: A Cancer Journal for Clinicians.","from":"paper-jemal-cancer-statistics-2007-cacancer-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping","note":"Kelly E, Russell SJ. Molecular Therapy.","from":"paper-kelly-russell-oncolytic-history-moltherapy-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","note":"Dimopoulos M, Spencer A, Attal M, et al. New England Journal of Medicine.","from":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","note":"Symmans WF, Peintinger F, Hatzis C, et al. Journal of Clinical Oncology.","from":"paper-symmans-j-clin-oncol","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","note":"Engelman JA, Zejnullahu K, Mitsudomi T, et al. Science.","from":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","note":"Slotman B, Faivre-Finn C, Kramer G, et al. New England Journal of Medicine.","from":"paper-slotman-n-engl-j-med","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","note":"Olsen E, Vonderheid E, Pimpinelli N, et al. Blood.","from":"paper-olsen-mycosis-fungoides-staging-blood-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","note":"Levine RL, Pardanani A, Tefferi A, et al. Nature Reviews Cancer.","from":"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","note":"Goonetilleke KS, Siriwardena AK. European Journal of Surgical Oncology.","from":"paper-goonetilleke-ca19-9-systematic-review-ejso-2007","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"The spindle-assembly checkpoint in space and time","note":"Musacchio A, Salmon ED. Nature reviews. Molecular cell biology.","from":"paper-musacchio-nat-rev-mol-cell-biol","refs":[]},{"group":"paper","date":"2007","precision":"year","title":"Triple-negative breast cancer: clinical features and patterns of recurrence","note":"Dent R, Trudeau M, Pritchard KI, et al. Clinical Cancer Research.","from":"paper-dent-tnbc-clinical-features-recurrence-ccr-2007","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","note":"JCO","from":"yuman-fong","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Bronchoplastic surgery for non-small-cell lung cancer (in Czech)","note":"Rozhledy v chirurgii","from":"petr-poloucek","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Cerebral Glutamine and Glutamate Levels in Relation to Compromised Energy Metabolism: A Microdialysis Study in Subarachnoid Hemorrhage Patients","note":"Journal of Cerebral Blood Flow & Metabolism","from":"carolina-samuelsson","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Cetuximab for the treatment of colorectal cancer (CO.17)","note":"NEJM","from":"tu-dongsheng","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323)","note":"NEJM","from":"jan-vermorken","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Complete Response From Thalidomide in Angiosarcoma After Treatment of Breast Cancer","note":"Journal of Clinical Oncology","from":"raina-vinod","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Compressing drug development timelines in oncology using phase '0' trials","note":"Nature Reviews Cancer","from":"shivaani-kummar","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Counting colonies of clonogenic assays by using densitometric software","note":"Radiation Oncology","from":"maximilian-niyazi","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled...","note":"Lancet","from":"matt-seymour","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties","note":"Proceedings of the National Academy of Sciences","from":"fernando-pelaez","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial (START)","note":"JCO","from":"kerry-courneya","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Free Functioning Muscle Transfer for Lower Extremity Posttraumatic Composite Structure and Functional Defect","note":"Plastic & Reconstructive Surgery","from":"chen-chien-tzung","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Genome-wide association study identifies novel breast cancer susceptibility loci","note":"Nature","from":"arto-mannermaa","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Granular cell tumors of the urinary bladder","note":"World Journal of Surgical Oncology","from":"farhat-abbas","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"High-resolution Computed Tomography Findings of Diffuse Pulmonary Involvement by Mycosis Fungoides","note":"Journal of Thoracic Imaging","from":"akifumi-takaori","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"History of oncolytic viruses: genesis to genetic engineering","note":"Molecular Therapy","from":"stephen-russell","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Hormone replacement therapy use and variations in the risk of breast cancer","note":"BJOG: An International Journal of Obstetrics & Gynaecology","from":"lucie-opatrny","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Human papillomavirus and cervical cancer","note":"Lancet","from":"mark-schiffman","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","note":"Nature","from":"daniel-haber","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials network...","note":"Journal of Clinical Oncology","from":"deborah-bruner","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors","note":"Nephrology Dialysis Transplantation","from":"josep-maria-campistol","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Long-term results after radical resections for pancreatic ductal adenocarcinoma (in Czech)","note":"Rozhledy v chirurgii","from":"petr-poloucek","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The...","note":"Journal of Clinical Oncology","from":"pilar-garrido","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","note":"Proceedings of the National Academy of Sciences","from":"chong-jen-yu","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer","note":"New England Journal of Medicine","from":"mitchell-schnall","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer (ACRIN 6667)","note":"NEJM","from":"constance-lehman","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"OLFACTORY GROOVE MENINGIOMAS","note":"Neurosurgery","from":"florian-roser","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial","note":"Lancet Oncology","from":"florian-lordick","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","note":"Blood","from":"sirpa-leppa","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Programmed anuclear cell death delimits platelet life span","note":"Cell","from":"benjamin-kile","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","note":"Journal of Clinical Oncology","from":"clifford-hudis","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Serum VEGF-C is associated with metastatic site in patients with malignant melanoma","note":"Acta Oncologica","from":"pia-vihinen","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","note":"NEJM","from":"robert-motzer","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Surgical removal of an embolised patent ductus arteriosus amplatzer occluding device in a 4-year-old girl","note":"Interact Cardiovasc Thorac Surg","from":"sulaiman-shahabuddin","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"TGF-β signaling alterations and susceptibility to colorectal cancer","note":"Human Molecular Genetics","from":"boris-pasche","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Trastuzumab--mechanism of action and use in clinical practice","note":"New England Journal of Medicine","from":"clifford-hudis","refs":[]},{"group":"person-paper","date":"2007","precision":"year","title":"Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells","note":"Proceedings of the National Academy of Sciences","from":"nakagama-hitoshi","refs":[]},{"group":"technology","date":"2007","precision":"year","title":"Bariatric surgery and cancer incidence","note":"First use in humans or first approval, as the technology record states it.","from":"bariatric-surgery-cancer-incidence","refs":[]},{"group":"technology","date":"2007","precision":"year","title":"HER2 tyrosine kinase inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"her2-tyrosine-kinase-inhibitors","refs":[]},{"group":"technology","date":"2007","precision":"year","title":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","note":"First use in humans or first approval, as the technology record states it.","from":"litt-systems","refs":[]},{"group":"technology","date":"2007","precision":"year","title":"Visual inspection with acetic acid (VIA) for cervical screening","note":"First use in humans or first approval, as the technology record states it.","from":"via-cervical-screening","refs":[]},{"group":"trial","date":"2007","precision":"year","title":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer reported","note":"Symptomatic brain metastases at 1 year 14.6% vs 40.4%; 1-year survival 27.1% vs 13.3%.","from":"slotman-pci-es-sclc","refs":["sclc","extensive-stage-sclc"]},{"group":"trial","date":"2007","precision":"year","title":"NCIC CO.17 reported","note":"Overall survival hazard ratio 0.77 (95% CI 0.64 to 0.92, p=0.005) against best supportive care alone; benefit confined to KRAS wild-type tumours.","from":"co-17","refs":["colorectal","cetuximab"]},{"group":"trial","date":"2007","precision":"year","title":"Photodynamic therapy against surgery for nodular basal cell carcinoma reported","note":"Five-year recurrence 14 per cent after methyl aminolevulinate photodynamic therapy against 4 per cent after excision (sustained complete response 76 against 96 per cent, p=0.01), w...","from":"mal-pdt-versus-surgery-nodular-bcc","refs":["basal-cell-carcinoma","skin-cancer","methyl-aminolevulinate"]},{"group":"trial","date":"2007","precision":"year","title":"QUASAR reported","note":"Relative risk of death 0.82 (0.70 to 0.95, p = 0.008) and of recurrence 0.78 (0.67 to 0.91, p = 0.001) with adjuvant fluorouracil and folinic acid; an absolute five-year survival g...","from":"quasar","refs":["colorectal","colon-cancer","fluorouracil","leucovorin"]},{"group":"trial","date":"2007","precision":"year","title":"WHEL (Women's Healthy Eating and Living) reported","note":"Breast cancer events 16.7% vs 16.9%; no effect on recurrence or mortality despite large dietary change.","from":"whel","refs":["breast-hr-positive","tnbc"]},{"group":"regulatory","date":"2007-11-16","precision":"day","title":"Sorafenib: approval (US)","note":"Unresectable HCC on SHARP","from":"sorafenib","refs":[]}]},"route":"/years/2007/","neighbours":{"year":[{"id":"2006","kind":"year","name":"2006 in oncology","route":"/years/2006/"},{"id":"2008","kind":"year","name":"2008 in oncology","route":"/years/2008/"}]}}